IL6 and prostate cancer: Similarly, Okamoto et al.’s [85] in vitro experiments pointed that IL-6 acts as a paracrine growth factor for androgen-sensitive and slow-growing prostate cancer cell lines (LNCaP) and as an autocrine growth factor for androgen-insensitive and fast-growing prostate cancer cell lines (DU145 and PC3).